P
Philogen
Develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders
About Philogen
Philogen is a Swiss-Italian biotechnology company founded in 1996, specializing in the development of innovative biopharmaceuticals for treating angiogenesis-related disorders, which involve the formation of new blood vessels. The company operates in the biopharmaceutical market, focusing on the discovery, GMP production, and clinical development of targeted therapeutics, particularly antibody-based treatments. Philogen serves large pharmaceutical companies through numerous collaborative agreements and partnerships. Its business model revolves around the development and commercialization of proprietary therapeutics, generating revenue through licensing deals, milestone payments, and royalties. The company leverages its expertise in antibody engineering and targeted drug delivery to maintain a leading position in its field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 183
- Open positions
- 11
- Dealroom signal
- 83.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Drug Development, Biotech and Pharma, Hard Tech, Longevity, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Mar 2021 | $69M | $690M | Undisclosed | ↗ |
| LATE VCOther financing | May 2019 | $68M | $273M | The Equity Club · Mediobanca | ↗ |
Growth signals
Latest recorded traffic for Philogen is 5.3K monthly website visits, down 8.6% over the last three months. Philogen's team grew 8.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Philogen in the Sovicille ecosystem
The Philogen office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
The Equity Club
Mediobanca
Other known investors2 additional known investors
Dompé farmaceutici
Nova Capital
Source: Dealroom Talent Intelligence.
See Philogen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









